There won't be any deal made until the company can demonstrate positive P2 data and even then who knows if Amarantus will want to take a deal. It appears that the game plan is to try and monetize the diagnostic division either by sales, spin off or outright sale of the division and use that money to fund the rest instead of having to give up any % of rights to MANF, ESS or ELTO. Partnership seems to be the only option if there is no other option. And I believe the company is comfortable in diluting rather than partner unless the partnership terms are in Amarantus' favor. And that type of deal rarely is offered by BP.